Crossmark

The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries

Crossref DOI link: https://doi.org/10.1007/s12325-017-0522-y

Published Online: 2017-04-10

Published Print: 2017-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gulácsi, László

Brodszky, Valentin

Baji, Petra

Rencz, Fanni

Péntek, Márta
Funding

Funding for this research was provided by:

Celltrion Healthcare
License Information

Text and Data Mining valid from 2017-04-10
More Information

Article History

Received: 3 March 2017

First Online: 10 April 2017